Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3337466 | 0.99 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1MAPTRAB9AGLA | |
| SCHEMBL3342606 | 0.89 | PPARG (0.33) | MAPTKMT2ACHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL3336966 | 0.88 | PPARG (0.32) | MAPTKMT2ACHRM5CHRM1CHRM3 | |
| SCHEMBL3336835 | 0.88 | HRH4 (0.37) | SMN1; SMN2KMT2ACHRM5CHRM1PPARG | |
| SCHEMBL3335362 | 0.88 | ROCK2 (0.40) | MAPT | |
| Hydrochloric Acid SCHEMBL3342562 | 0.87 | HRH4 (0.36) | SMN1; SMN2KMT2ACHRM5CHRM1PPARG | |
| Hydrochloric Acid SCHEMBL3625843 | 0.87 | ROCK2 (0.39) | MAPT | |
| Hydrochloric Acid SCHEMBL3335270 | 0.87 | ROCK2 (0.39) | MAPT | |
| SCHEMBL3336440 | 0.86 | MEN1 (0.34) | SMN1; SMN2KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3336893 | 0.85 | MEN1 (0.34) | SMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202227-B1 | NOVEL HISTIDINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-8324261-B2 | Histidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| EP-2202227-A1 | NOVEL HISTIDINE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20100152459-A1 | NOVEL HISTIDINE DERIVATIVES | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152459-A1 | NOVEL HISTIDINE DERIVATIVES | HRH4, HNMT, HRH3 | SMN1; SMN2 2519/4885NPC1 2171/4885MAPT 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.